Next Science Limited
NXSCF · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.04 | 0.10 | -0.06 | 0.59 |
| FCF Yield | -41.90% | -32.43% | -19.90% | -4.89% |
| EV / EBITDA | -2.35 | -2.83 | -7.02 | -18.49 |
| Quality | ||||
| ROIC | -160.01% | -109.18% | -102.76% | -74.39% |
| Gross Margin | 80.83% | 73.20% | 101.64% | 66.37% |
| Cash Conversion Ratio | 0.75 | 0.63 | 0.93 | 0.85 |
| Growth | ||||
| Revenue 3-Year CAGR | 24.89% | 35.34% | 50.43% | 29.61% |
| Free Cash Flow Growth | 46.36% | 9.89% | -104.00% | 38.18% |
| Safety | ||||
| Net Debt / EBITDA | -0.09 | 0.57 | 0.53 | 0.73 |
| Interest Coverage | -36.29 | -21.68 | -451.84 | -583.15 |
| Efficiency | ||||
| Inventory Turnover | 6.02 | 8.24 | 5.73 | 1.81 |
| Cash Conversion Cycle | 36.51 | 16.71 | 46.70 | 168.63 |